Corvus Pharmaceuticals, Inc. Other Noncash Income (Expense)
Corvus Pharmaceuticals, Inc. (CRVS) reported Other Noncash Income (Expense) of -$47.00 thousand for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-10-29.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2019-10-29
- Corvus Pharmaceuticals, Inc. other noncash income (expense) for the quarter ending 2019-09-30 was $39.00K, a 66.38% decline year-over-year.
- Corvus Pharmaceuticals, Inc. other noncash income (expense) for the quarter ending 2019-06-30 was $33.00K, a 71.05% decline year-over-year.
- Corvus Pharmaceuticals, Inc. other noncash income (expense) for the quarter ending 2019-03-31 was -$119.00K, a 203.48% decline year-over-year.
- Corvus Pharmaceuticals, Inc. other noncash income (expense) for the quarter ending 2018-09-30 was $116.00K.
- Corvus Pharmaceuticals, Inc. other noncash income (expense) for fiscal 2015 was -$40.00K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2019-09-30 | $39.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-29 | $72.00K derived: sum of 2 quarters · filed 2019-10-29 | -$47.00K 10-Q · filed 2019-10-29 | |
| 2019-06-30 | $33.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$86.00K 10-Q · filed 2019-08-01 | ||
| 2019-03-31 | -$119.00K 10-Q · filed 2019-05-09 | |||
| 2018-09-30 | $116.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-29 | $230.00K derived: sum of 2 quarters · filed 2019-10-29 | $345.00K 10-Q · filed 2019-10-29 | |
| 2018-06-30 | $114.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $229.00K 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $115.00K 10-Q · filed 2019-05-09 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$40.00K 10-K · filed 2018-03-01 | ||
| 2015-09-30 | -$40.00K 10-Q · filed 2016-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |